Similar articles

• [Suspected cases of severe side effects after infliximab (Remicade) in Germany].

  Andus T, Stange EF, Höffler D, Keller-Stanislawski B. Andus T, et al. Med Klin (Munich). 2003 Aug 15;98(8):429-36. doi: 10.1007/s00063-003-1282-9. Med Klin (Munich). 2003. PMID: 12928808 German.
• [Remicade in therapy of rheumatoid arthritis and Crohn diseases--no reason for panic].

  Kalden JR, Lochs H, Wollheim H. Kalden JR, et al. Z Rheumatol. 2002 Aug;61(4):466-8. doi: 10.1007/s00393-002-0401-y. Z Rheumatol. 2002. PMID: 12426854 German. No abstract available.
• Recommendations for the prevention and management of tuberculosis in patients taking infliximab.

  Salmon-Ceron D; Groupe Recherche Anti-TNF et Infections Opportunistes; Agence Française de Sécurité Sanitaire des Produits de Santé. Salmon-Ceron D, et al. Ann Med Interne (Paris). 2002 Nov;153(7):429-31. Ann Med Interne (Paris). 2002. PMID: 12598827
• [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].

  Manger B; Kommission Pharmkotherapie, Deutsche Gesellschaft für Rheumatologie. Manger B, et al. Z Rheumatol. 2002 Dec;61(6):694-7. doi: 10.1007/s00393-002-0451-1. Z Rheumatol. 2002. PMID: 12491133 Review. German. No abstract available.
• Infliximab.

  Valle E, Gross M, Bickston SJ. Valle E, et al. Expert Opin Pharmacother. 2001 Jun;2(6):1015-25. doi: 10.1517/14656566.2.6.1015. Expert Opin Pharmacother. 2001. PMID: 11585004 Review.